10268-65-2

Upstream product

• 15216-81-6 5-chloro-2-hydroxybenzoyl chloride 
• 108-95-2 phenol 
• 321-14-2 5-chloro-2-hydroxybenzoic acid 
• 64-17-5 ethanol 
• 7782-50-5 chlorine 
• 118-55-8 phenyl Salicylate 

Downstream Products

• 25225-73-4 6-chloro-2-phenyl-4H-benzo[e][1,3]oxazin-4-one 
• 57786-55-7 5-Chloro-2-hydroxy-N-pyridin-2-ylmethyl-benzamide 
• 329944-68-5 (5-chloro-2-hydroxyphenyl)(3,5-dimethylphenyl)methanone 
• 51589-63-0 1-acetoxy-2-benzooxazol-2-yl-4-chloro-benzene 
• 81268-47-5 N-(1H-benzimidazol-2-yl)-5-chloro-2-hydroxybenzamide 

Relevant academic research and scientific papers

Integrating Metal-Catalyzed C-H and C-O Functionalization to Achieve Sterically Controlled Regioselectivity in Arene Acylation

One major goal of organometallic chemists is the direct functionalization of the bonds most recurrent in organic molecules: C-H, C-C, C-O, and C-N. An even grander challenge is C-C bond formation when both precursors are of this category. Parallel to this is the synthetic goal of achieving reaction selectivity that contrasts with conventional methods. Electrophilic aromatic substitution (EAS) via Friedel-Crafts acylation is the most renowned method for the synthesis of aryl ketones, a common structural motif of many pharmaceuticals, agrochemicals, fragrances, dyes, and other commodity chemicals. However, an EAS synthetic strategy is only effective if the desired site for acylation is in accordance with the electronic-controlled regioselectivity of the reaction. Herein we report steric-controlled regioselective arene acylation with salicylate esters via iridium catalysis to access distinctly substituted benzophenones. Experimental and computational data indicate a unique reaction mechanism that integrates C-O activation and C-H activation with a single iridium catalyst without an exogenous oxidant or base. We disclose an extensive exploration of the synthetic scope of both the arene and the ester components, culminating in the concise synthesis of the potent anticancer agent hydroxyphenstatin.

NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER

2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.

A new group of potential antituberculotics: N-(2-pyridylmethyl) salicylamides and N-(3-pyridylmethyl)salicylamides

As a part of our systematic study of antimycobacterially active derivatives of salicylamides, a series of nineteen derivatives of N-(2-pyridylmethyl) salicylamides and N-(3-pyridylmethyl)salicylamides was synthesised. The compounds exhibited in vitro activity against Mycobacterium tuberculosis and M. avium. Their lipophilicity, RM, was measured by thin layer chromatography on silica gel impregnated with trioctadecylsilane and the logarithm of the partition coefficient (octanol-water), logP, was calculated. Both the parameters of lipophilicity correlated. The quantitative relationship between the structure and antimycobacterial activity was calculated. Antimycobacterial activity increased with an increase in lipophilicity. The N-(2-pyridylmethyl)salicylamide derivatives were more active than the derivatives of isomeric N-(3-pyridylmethyl)salicylamides. The geometry of compounds was calculated and the calculation was verified by measuring the length of the hydrogen bond between hydroxyl and carbonyl groups on the salicylic moiety.